Valneva CMO Juan Carlos Jaramillo
December 6, 2021 07:26 AM ESTUpdated 08:30 AM
Coronavirus

Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new an­tivi­ral — re­port

Amber Tong

Senior Editor

Paul Schloesser

Associate Editor

Falling way be­hind the fron­trun­ners in de­liv­er­ing a Covid-19 vac­cine, French biotech Val­ne­va has placed high hopes on boost­ers.

Which may be why it is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times